Novo Nordisk has concluded 2025 with impressive sales growth, primarily fueled by its obesity treatment offerings and strong performance in the U.S. market. However, its operating profits have shown signs of caution, suggesting a more reserved outlook for 2026 as the company adapts to increasing competition and pricing pressures.
The company achieved remarkable growth at constant exchange rates throughout 2025, yet the reported figures, particularly for the fourth quarter, indicate challenges ahead. These challenges arise from various factors, including the costs associated with ongoing transformations and the early effects of intensified competition in the global GLP-1 market.
Sales Performance Overview
In 2025, Novo Nordisk reported a sales increase exceeding 10% at constant exchange rates, with operating profits rising by 6%. This performance fell within the previously communicated guidance, highlighting the company’s resilience. Total net sales reached $43.27 billion, while operating profit stood at $17.88 billion at constant exchange rates. However, when expressed in reported U.S. dollars, operating profit saw a slight decline of 1%. This decrease was largely due to currency fluctuations and approximately $1.12 billion in expenses linked to a company-wide transformation initiative. Had these costs been excluded, the operating profit growth would have been significantly higher.
The geographic performance of Novo Nordisk varied, with U.S. operations achieving an 8% sales increase at constant exchange rates, bolstered by favorable gross-to-net sales adjustments. In contrast, international operations experienced an even more robust growth rate of 14% at constant exchange rates. A significant driver of this success was the obesity care segment, which saw a staggering 31% growth at constant exchange rates. This surge offset the more modest growth in GLP-1 diabetes treatments and slower expansion in rare diseases.
Fourth Quarter Challenges
The fourth quarter of 2025 presented a different narrative, with sales declining by 2% and operating profit decreasing by 4% at constant exchange rates. These results underscore the challenges posed by shifting pricing dynamics and increased competitive intensity. Novo Nordisk’s management has indicated that these pressures are likely to escalate in 2026, particularly in the U.S. market. Factors such as lower realized prices, reductions in Medicaid coverage for obesity treatments, and the implications of the “Most Favored Nations” pricing agreement are expected to have a substantial impact on the company’s performance.
Adjusted Outlook for 2026
Looking ahead, Novo Nordisk’s projections for 2026 reflect a cautious adjustment. The company’s outlook, excluding the non-recurring reversal of $4.2 billion in 340B Drug Pricing Program rebate provisions, anticipates a decline in both sales and operating profit between 5% and 13% at constant exchange rates. This forecast takes into account the loss of exclusivity for its semaglutide molecule in certain international markets, along with the absence of the favorable U.S. gross-to-net adjustments that positively influenced 2025 results.
While the global GLP-1 market is poised for continued expansion, management acknowledges that volume growth will increasingly be counterbalanced by lower prices and heightened competition, necessitating a strategic response.
Leadership Transition and Market Strategy
Mike Doustdar, who stepped into the role of president and CEO in July 2025, characterized the past year as both resilient and challenging. He highlighted the company’s ability to achieve 10% sales growth at constant exchange rates while reaching nearly 46 million individuals with innovative treatments. Looking forward, Doustdar emphasized the anticipated pricing challenges in an increasingly competitive landscape. Nonetheless, he expressed optimism regarding the early uptake of the recently launched oral Wegovy pill, which was approved by the FDA in late December and made available in January. This product’s performance will be pivotal in determining Novo Nordisk’s capacity to expand access amid reimbursement and channel mix challenges.
Long-Term Confidence and Shareholder Returns
Despite the short-term challenges, Novo Nordisk is signaling long-term confidence through strategic capital returns. The company has proposed an increased dividend and initiated a $2.1 billion share repurchase program. This initiative aims to reduce share capital while fulfilling obligations tied to share-based incentive programs, underscoring a commitment to delivering value to shareholders.
Key Takeaways
- Novo Nordisk experienced over 10% sales growth in 2025, primarily driven by its obesity care segment.
-
Despite strong sales, the company’s operating profit faced pressures from transformation costs and competitive dynamics.
-
The 2026 outlook anticipates a decline in sales and operating profit due to pricing challenges and loss of exclusivity for key products.
-
Leadership changes and strategic initiatives, including the launch of the oral Wegovy pill, signify the company’s efforts to navigate a competitive landscape.
-
Long-term confidence is reflected in increased dividends and a substantial share repurchase program.
In conclusion, Novo Nordisk’s 2025 performance illustrates a company navigating both growth and challenges. With a keen focus on strategic initiatives and an eye on market dynamics, Novo Nordisk aims to maintain its position in the evolving biopharma landscape, even as it braces for a more competitive 2026.
Read more → www.pharmexec.com